Teva Pharmaceutical Industries Ltd., of Jerusalem, said it completed the acquisition of Auspex Pharmaceuticals Inc., of La Jolla, Calif., in a roughly $3.2 billion deal that gives Teva rights to Auspex's orphan drug pipeline, including lead compound SD-809 (deutetrabenazine) for the potential treatment of chorea associated with Huntington's disease, tardive dyskinesia and Tourette syndrome.